Novavax Files 8-K on Financials
Ticker: NVAX · Form: 8-K · Filed: Nov 6, 2025 · CIK: 1000694
| Field | Detail |
|---|---|
| Company | Novavax Inc (NVAX) |
| Form Type | 8-K |
| Filed Date | Nov 6, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-condition, sec-filing
Related Tickers: NVVX
TL;DR
NVAX filed an 8-K for financial updates, check for details.
AI Summary
On November 6, 2025, Novavax, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well as financial statements and exhibits. No specific financial figures or significant events were detailed in the provided excerpt.
Why It Matters
This filing indicates Novavax is providing updates on its financial performance and condition to the SEC, which is crucial for investors to assess the company's health.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of financial information and does not appear to contain any immediate negative news.
Key Players & Entities
- NOVAVAX INC (company) — Registrant
- November 6, 2025 (date) — Date of Report
- 700 Quince Orchard Road Gaithersburg, Maryland 20878 (address) — Principal Executive Offices
FAQ
What specific financial results are being reported by Novavax in this 8-K?
The provided excerpt states the 8-K concerns 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits,' but does not detail specific figures.
When was this 8-K filing submitted to the SEC?
The filing was submitted on November 6, 2025.
What is Novavax's principal executive office address?
Novavax's principal executive offices are located at 700 Quince Orchard Road, Gaithersburg, Maryland 20878.
What is the SEC file number for Novavax?
Novavax's SEC file number is 000-26770.
What is the SIC code for Novavax?
Novavax's Standard Industrial Classification (SIC) code is 2836, for Biological Products (No Diagnostic Substances).
Filing Stats: 452 words · 2 min read · ~2 pages · Grade level 9.4 · Accepted 2025-11-06 08:00:22
Key Financial Figures
- $0.01 — ch registered Common Stock, Par Value $0.01 per share NVAX The Nasdaq Global Select
Filing Documents
- nvax-20251106.htm (8-K) — 35KB
- nvax3q25earningspressrelea.htm (EX-99.1) — 144KB
- image_0.jpg (GRAPHIC) — 5KB
- 0001000694-25-000048.txt ( ) — 316KB
- nvax-20251106.xsd (EX-101.SCH) — 2KB
- nvax-20251106_lab.xml (EX-101.LAB) — 21KB
- nvax-20251106_pre.xml (EX-101.PRE) — 12KB
- nvax-20251106_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. Third Quarter Financial Results On November 6, 2025, Novavax, Inc. (the "Company") issued a press release announcing the Company's financial results for the quarter ended September 30, 2025. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release, dated November 6, 2025, regarding the Company's financial results for the quarter ended September 30, 2025. 104 Cover Page Interactive Data File (formatted as Inline XBRL).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NOVAVAX, INC. Date: November 6, 2025 By: /s/ Mark J. Casey Name: Mark J. Casey Title: Executive Vice President, Chief Legal Officer and Corporate Secretary